Redx Pharma has a new Chairman of the Board of Directors and a Non-Executive Director of the company.
The research and development company has appointed Iain Ross to the position. Ross will begin with his duties from May 1, 2017.
Ross has over 35 years’ of experience having held Senior Board and Management positions at multiple public and private companies in the life sciences sector.
Iain Ross, incoming Chairman of Redx Pharma, commented on his appointment: “Redx Pharma is a business of the highest quality that has discovered high value assets in cancer, immunology and infection and the opportunity to be part of progressing these promising assets through the clinic was instantly appealing. I look forward to working with the Board to realise the value of our best-in-class assets: RXC004 – Porcupine inhibitor and RXC005 – reversible BTK inhibitor, alongside several other promising assets in the Company’s pipeline.”